Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

896.10 -22.12 (-2.41%)
Streaming Delayed Price Updated: 11:33 AM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 149,753
Open 915.84
Bid (Size) 894.87 (200)
Ask (Size) 897.33 (40)
Prev. Close 918.22
Today's Range 894.05 - 919.16
52wk Range 590.78 - 953.58
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102 ↗
argenex (NASDAQ:ARGX) said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for... 
Via MarketBeat
Topics Intellectual Property
News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
From Forte Biosciences, Inc.
Via Business Wire

Performance

YTD
+6.7%
+6.7%
1 Month
+1.0%
+1.0%
3 Month
+14.3%
+14.3%
6 Month
+7.6%
+7.6%
1 Year
+50.6%
+50.6%

More News

Read More
News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
From argenx SE
Via GlobeNewswire
News headline image
argenex Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx to Host Autoimmune Myositis R&D Webinar
From argenx SE
Via GlobeNewswire
News headline image
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near ↗
Via MarketBeat
Topics Intellectual Property Supply Chain
News headline image
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference ↗
Via MarketBeat
Topics Intellectual Property
News headline image
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
From argenx SE
Via GlobeNewswire
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
Via The Motley Fool
News headline image
argenx to Host Myositis R&D Webinar on June 23, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
Via The Motley Fool
News headline image
2 Ways to Play the Big Pharma Patent Cliff ↗
Via MarketBeat
Topics ETFs Intellectual Property
News headline image
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at BofA Securities 2026 Health Care Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
From argenx SE
Via GlobeNewswire
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
argenx announces Annual General Meeting of Shareholders on May 6, 2026
From argenx SE
Via GlobeNewswire

Frequently Asked Questions

Is argenx SE - American Depositary Shares publicly traded?
Yes, argenx SE - American Depositary Shares is publicly traded.
What exchange does argenx SE - American Depositary Shares trade on?
argenx SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for argenx SE - American Depositary Shares?
The ticker symbol for argenx SE - American Depositary Shares is ARGX on the Nasdaq Stock Market
What is the current price of argenx SE - American Depositary Shares?
The current price of argenx SE - American Depositary Shares is 896.10
When was argenx SE - American Depositary Shares last traded?
The last trade of argenx SE - American Depositary Shares was at 07/27/26 11:33 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.